Shopping Cart 0
Cart Subtotal
USD 0

Soligenix Inc (SNGX) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Soligenix Inc (SNGX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Soligenix Inc (Soligenix) is a late-stage biopharmaceutical company which focuses on the development of products for the treatment of serious inflammatory diseases and biodefense counter measures. It develops biotherapeutics for the treatment of orphan diseases such as cutaneous T-cell lymphoma, pediatric Crohn's disease, oral mucositis and acute radiation enteritis. It develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the treatment of gastrointestinal disorders that are characterized by high inflammation, including pediatric Crohn's disease, acute radiation enteritis and oral mucositis. The company has active development programs for RiVax, a ricin toxin vaccine; VeloThrax, an anthrax vaccine; and OrbeShield, a gastrointestinal acute radiation syndrome therapeutic. These vaccine programs are supported by ThermoVax, a heat stabilization technology. Soligenix is headquartered in Princeton, New Jersey, the US.

Soligenix Inc Key Recent Developments

Jun 28,2018: Soligenix, Prices USD8,000,000 Public Offering At The Market

May 11,2018: Soligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results

Mar 15,2018: Soligenix Announces Recent Accomplishments And Year-End 2017 Financial Results

Jan 25,2018: Soligenix-Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials

Nov 30,2017: Soligenix to Receive USD417,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Soligenix Inc-Key Facts 6

Soligenix Inc-Key Employees 7

Soligenix Inc-Key Employee Biographies 8

Soligenix Inc-Major Products and Services 9

Soligenix Inc-History 10

Soligenix Inc-Company Statement 14

Soligenix Inc-Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2-Company Analysis 16

Company Overview 16

Soligenix Inc-Business Description 17

Business Segment: BioTherapeutics Segment 17

Overview 17

Performance 17

Business Segment: Vaccines/BioDefense Segment 17

Overview 17

Performance 17

Soligenix Inc-SWOT Analysis 18

SWOT Analysis-Overview 18

Soligenix Inc-Strengths 18

Soligenix Inc-Weaknesses 19

Soligenix Inc-Opportunities 20

Soligenix Inc-Threats 21

Soligenix Inc-Key Competitors 22

Section 3-Company Financial Ratios 23

Financial Ratios-Capital Market Ratios 23

Financial Ratios-Annual Ratios 24

Performance Chart 26

Financial Performance 26

Financial Ratios-Interim Ratios 27

Financial Ratios-Ratio Charts 28

Section 4-Company's Lifesciences Financial Deals and Alliances 29

Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

Soligenix Inc, Recent Deals Summary 31

Section 5-Company's Recent Developments 32

Jun 28, 2018: Soligenix, Prices USD8,000,000 Public Offering At The Market 32

May 11, 2018: Soligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results 33

Mar 15, 2018: Soligenix Announces Recent Accomplishments And Year-End 2017 Financial Results 34

Jan 25, 2018: Soligenix-Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials 35

Nov 30, 2017: Soligenix to Receive USD417,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program 38

Nov 06, 2017: Soligenix Announces Recent Accomplishments And Third Quarter 2017 Financial Results 39

Aug 11, 2017: Soligenix Announces Recent Accomplishments And Second Quarter 2017 Financial Results 40

May 11, 2017: Soligenix Announces Recent Accomplishments And First Quarter 2017 Financial Results 42

Mar 27, 2017: Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results 44

Section 6-Appendix 46

Methodology 46

Ratio Definitions 46

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Soligenix Inc, Performance Chart (2013-2017) 26

Soligenix Inc, Ratio Charts 28

Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Soligenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30


List Of Table

List of Tables

Soligenix Inc, Key Facts 6

Soligenix Inc, Key Employees 7

Soligenix Inc, Key Employee Biographies 8

Soligenix Inc, Major Products and Services 9

Soligenix Inc, History 10

Soligenix Inc, Subsidiaries 15

Soligenix Inc, Key Competitors 22

Soligenix Inc, Ratios based on current share price 23

Soligenix Inc, Annual Ratios 24

Soligenix Inc, Annual Ratios (Cont...1) 25

Soligenix Inc, Interim Ratios 27

Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

Soligenix Inc, Recent Deals Summary 31

Currency Codes 46

Capital Market Ratios 46

Equity Ratios 47

Profitability Ratios 47

Cost Ratios 48

Liquidity Ratios 48

Leverage Ratios 49

Efficiency Ratios 49

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Soligenix Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

PDL BioPharma Inc

Panacea Biotec Ltd

Osiris Therapeutics Inc

Novartis AG

Emergent BioSolutions Inc

Dynavax Technologies Corp

Cellphire Inc